Results 171 to 180 of about 1,795 (205)

Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis

Archives of Osteoporosis, 2023
Rong-zhi Chen, Changshun Chen, Bin Geng, C. Yang, Hefang Xiao, Fei Yang, Hao Wang, Yayi Xia   +7 more
semanticscholar   +1 more source

Interaction mechanism of a cysteine protease inhibitor, odanacatib, with human serum albumin: In vitro and bioinformatics studies.

Biophysical Chemistry, 2023
Nurul Jannah Mohd Asngari, Khairul Azreena Bakar, S. Feroz, F. A. Razak, Adyani Azizah Abd Halim   +4 more
semanticscholar   +1 more source

Effect of Odanacatib on the release of NTX (Amino Terminal Telopeptide) from LPS contaminated type I dentin collagen.

Dental Materials, 2023
A. Bafail, K. Carneiro, A. Kishen, A. Prakki   +3 more
semanticscholar   +1 more source

Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study

Osteoporosis International, 2022
L. Duong, S. Clark, M. Pickarski, H. Giezek, D. Cohn, R. Massaad, S. Stoch   +6 more
semanticscholar   +1 more source

Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible

Bone, 2014
The cathepsin K (CatK) inhibitor odanacatib (ODN) is currently being developed for the treatment of osteoporosis. In clinical trials, efficacy and resolution of effect of ODN treatment on bone turnover biomarkers and accrued bone mass have been demonstrated.
Y, Zhuo, J-Y, Gauthier, W C, Black, M D, Percival, L T, Duong   +4 more
openaire   +2 more sources

Odanacatib for the treatment of postmenopausal osteoporosis.

Expert opinion on pharmacotherapy, 2014
The market of antiosteoporosis drugs has been declining in recent years, possibly in part due to the publicity around adverse events observed with bisphosphonates. Also, the proportion of patients with clinical fracture who receive adequate treatment remains low. Hence, there are still unmet needs in this field.
openaire   +1 more source

Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis

Osteoporosis International, 2020
N. Binkley, E. Orwoll, R. Chapurlat, B. Langdahl, B. Scott, H. Giezek, C. SantoraArthur   +6 more
semanticscholar   +1 more source

A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor

Journal of Pharmacokinetics and Pharmacodynamics, 2020
S. Zajic, S. Stoch, J. McCrea, R. Witter, Ghassan N. Fayad, M. Martinho, Julie A. Stone   +6 more
semanticscholar   +1 more source

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.

The Lancet Diabetes and Endocrinology, 2019
M. McClung, M. O’Donoghue, S. Papapoulos, H. Bone, B. Langdahl, K. Saag, I. Reid, D. Kiel, I. Cavallari, M. Bonaca, S. Wiviott, T. de Villiers, X. Ling, K. Lippuner, Toshitaka Nakamura, J. Reginster, J. A. Rodriguez-Portales, C. Roux, J. Zanchetta, C. Zerbini, Jeong-Gun Park, K. Im, Abby L. Cange, L. Grip, Norman L Heyden, C. Dasilva, D. Cohn, R. Massaad, B. Scott, N. Verbruggen, D. Gurner, Deborah L. Miller, M. Blair, A. Polis, S. Stoch, A. Santora, A. Lombardi, A. Leung, K. Kaufman, M. Sabatine   +39 more
semanticscholar   +1 more source

Odanacatib/prednisone withdrawal

Reactions Weekly, 2018
openaire   +1 more source